4/25
10:04 pm
meso
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27% [Yahoo! Finance]
Low
Report
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27% [Yahoo! Finance]
4/12
10:38 am
meso
Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]
Medium
Report
Degenerative Disc Disease Market Forecast - 2032; NSAIDs, Opioids, and others are major revenue generators [Yahoo! Finance]
4/11
09:19 am
meso
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]
Low
Report
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc. [Yahoo! Finance]
4/10
01:39 pm
meso
Mesoblast Limited: Back From The Dead [Seeking Alpha]
Neutral
Report
Mesoblast Limited: Back From The Dead [Seeking Alpha]
4/2
11:06 pm
meso
Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/25
10:42 pm
meso
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
High
Report
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
3/25
10:34 pm
meso
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
High
Report
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
3/13
07:30 pm
meso
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Low
Report
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
3/10
07:59 pm
meso
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) [Yahoo! Finance]
High
Report
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) [Yahoo! Finance]
3/10
07:54 pm
meso
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
High
Report
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
3/4
11:05 pm
meso
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/3
08:24 am
meso
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
2/28
05:59 pm
meso
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 [Yahoo! Finance]
Medium
Report
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 [Yahoo! Finance]
2/28
05:57 pm
meso
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Medium
Report
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
2/26
07:07 am
meso
Mesoblast Financial Results and Corporate Update Webcast [Yahoo! Finance]
Low
Report
Mesoblast Financial Results and Corporate Update Webcast [Yahoo! Finance]
2/26
07:00 am
meso
Mesoblast Financial Results and Corporate Update Webcast
Low
Report
Mesoblast Financial Results and Corporate Update Webcast
2/14
07:53 pm
meso
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease [Yahoo! Finance]
Medium
Report
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease [Yahoo! Finance]
2/14
07:46 pm
meso
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Low
Report
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
2/13
01:24 am
meso
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com to a "sell" rating.
1/30
09:22 pm
meso
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 [Yahoo! Finance]
Medium
Report
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 [Yahoo! Finance]
1/30
09:13 pm
meso
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Medium
Report
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
1/26
10:34 pm
meso
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at StockNews.com to a "sell" rating.